专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP3778897B1 IMMUNO-ONCOLYTIC THERAPIES 有权
公开(公告)号：EP3778897B1
公开(公告)日：2023-12-20
申请号：EP20189155.3
申请日：2014-08-22
发明人： THORNE, Stephen Howard
IPC分类号： C12N15/39 , A61K39/285 , A61K35/768 , C12N7/00

2. 发明公开

EP4267181A1 NUCLEIC ACID STABILIZING SOLUTION FOR VACCINES, THERAPY, DIAGNOSTICS, STORAGE, AND TRANSPORT 审中-实审
公开(公告)号：EP4267181A1
公开(公告)日：2023-11-01
申请号：EP21911865.0
申请日：2021-12-03
申请人： Daykin Molecular Systems, LLC
发明人： AGHAJANI, Erik , PHILLIPS, John , RUDDERMAN, Randal , MULLEN, Robert
IPC分类号： A61K39/285 , A61K47/18 , A61K47/26

3. 发明公开

EP4061417A1 VACCINIA VIRUSES AND METHODS FOR USING VACCINIA VIRUSES 审中-实审
公开(公告)号：EP4061417A1
公开(公告)日：2022-09-28
申请号：EP20889840.3
申请日：2020-11-20
申请人： University of Pittsburgh - of the Commonwealth System of Higher Education
发明人： BARTLETT, David , GUO, Zongsheng , LIU, Zuqiang
IPC分类号： A61K39/285 , A61K48/00 , A61K39/12 , C12N7/00 , C12N15/86 , C12Q1/70

4. 发明公开

EP3870217A1 MUTANT VACCINIA VIRUSES AND USE THEREOF 审中-公开
公开(公告)号：EP3870217A1
公开(公告)日：2021-09-01
申请号：EP19877342.6
申请日：2019-10-21
申请人： Icellkealex Therapeutics LLC
发明人： SONG, Xiaotong , VISKOVSKA, Mariya , GOMES MEDAGLIA, Maria Luiza
IPC分类号： A61K39/275 , A61K39/285 , A61K48/00 , C07K14/07 , C12N7/00 , C12N7/01 , C12N15/863 , C12N15/869

5. 发明公开

EP3863669A1 ONCOLYTIC VACCINIA VIRUS WITH MODIFIED B5R GENE FOR THE TREATMENT OF CANCER 审中-实审
公开(公告)号：EP3863669A1
公开(公告)日：2021-08-18
申请号：EP19794623.9
申请日：2019-10-10
申请人： Queen Mary University of London
发明人： WANG, Yaohe , YUAN, Ming
IPC分类号： A61K39/285 , A61K38/20 , A61K39/00

6. 发明公开

EP3419654A1 PROTEINS AND NUCLEIC ACIDS USEFUL IN VACCINES TARGETING STAPHYLOCOCCUS AUREUS 有权转让
公开(公告)号：EP3419654A1
公开(公告)日：2019-01-02
申请号：EP17706758.4
申请日：2017-02-22
申请人： Evaxion Biotech ApS
发明人： IVERSEN MØLLER, Niels , HOLM MATTSSON, Andreas
IPC分类号： A61K39/00 , A61K39/285 , C07K14/31 , C12N5/00

7. 发明授权

EP2596801B1 RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS ENCODING A HER-2 ANTIGEN FOR USE IN TREATING CANCER 有权转让
标题翻译：编码HER-2抗原用于治疗癌症的重组修饰的痘苗病毒安卡拉病毒
公开(公告)号：EP2596801B1
公开(公告)日：2018-05-02
申请号：EP13154196.3
申请日：2007-10-05
申请人： Bavarian Nordic A/S
发明人： Delcayre, Alain , Laus, Reiner , Mandl, Stefanie
IPC分类号： A61K39/00 , C07K14/47 , A61K39/285 , A61P35/00
CPC分类号： A61K39/0011 , A61K31/337 , A61K2039/55544 , A61K2039/55566 , C12N2710/24143 , C12N2830/60 , A61K2300/00
摘要： The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.

8. 发明公开

EP3283088A1 USE OF MVA OR MVADELTAE3L AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS 审中-公开
标题翻译：使用MVA或MVADELTAE3L作为免疫治疗药物治疗实体瘤
公开(公告)号：EP3283088A1
公开(公告)日：2018-02-21
申请号：EP16781031.6
申请日：2016-04-18
申请人： Memorial Sloan-Kettering Cancer Center
发明人： DENG, Liang , WOLCHOK, Jedd , MERGHOUB, Taha , SHUMAN, Stewart , DAI, Peihong , WANG, Weiyi
IPC分类号： A61K35/76 , A61K39/285 , A61K39/295 , A61P35/00 , C12N7/01
CPC分类号： A61K35/768 , A61K39/12 , A61K39/3955 , A61K2039/505 , A61K2039/525 , A61K2039/5254 , A61K2039/54 , A61K2039/545 , A61K2039/57 , C07K16/2818 , C07K16/2827 , C12N2710/24122 , C12N2710/24132 , C12N2710/24134 , C12N2710/24171 , A61K2300/00
摘要： The present disclosure relates to modified vaccinia Ankara (MVA) virus or MVAAE3L delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to mount an immune response against the tumor.

9. 发明授权

EP1420822B2 MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES 有权转让
标题翻译：修饰的痘苗病毒安卡拉用于接种新生儿
公开(公告)号：EP1420822B2
公开(公告)日：2017-07-05
申请号：EP03732280.7
申请日：2003-04-16
申请人： Bavarian Nordic A/S
发明人： CHAPLIN, Paul , SUTER, Mark , ACKERMANN, Mathias , FRANCHINI, Marco , VOLLSTEDT, Sabine , HEFTI, Hans, Peter
IPC分类号： A61K39/285 , A61K39/245
CPC分类号： A61K39/285 , A61K39/12 , A61K39/245 , A61K2039/5254 , A61K2039/55 , A61K2039/58 , C12N7/00 , C12N2710/16634 , C12N2710/24134 , C12N2710/24143 , C12N2710/24151 , C12N2710/24161 , Y02A50/386 , Y02A50/39 , Y02A50/394
摘要： The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL-12.
摘要翻译：本发明涉及使用病毒制备用于接种或治疗新生儿或产前动物（包括人）的药物，其中所述病毒能够感染新生儿或产前动物（包括人）的细胞，但不能在新生儿或产前动物（包括人类）中复制为感染性后代病毒。该病毒优选是改良的安卡拉痘苗病毒。具体地说，本发明涉及新生儿接种疫苗以防止与用于疫苗接种的病毒属于同一病毒组的病毒感染。此外，本发明涉及新生儿针对选自外来抗原和肿瘤抗原的抗原的疫苗接种，其中肿瘤抗原和/或外源抗原不同于与病毒相关的抗原。本发明进一步涉及如上定义的病毒用于增加激活树突细胞或其前体细胞和/或增加树突细胞或其前体细胞数量和/或增加产生和/或细胞的因子水平干扰素（IFN）或IL-12的含量。

10. 发明授权

EP2358387B1 VACCINE FORMULATIONS AND USES THEREOF 有权转让
标题翻译：疫苗制剂及其用途
公开(公告)号：EP2358387B1
公开(公告)日：2017-04-19
申请号：EP09752694.1
申请日：2009-11-13
申请人： Nanotherapeutics, Inc.
发明人： OBERREITHER, Manfred , TAUER, Christa , FALKNER, Falko-Guenter
IPC分类号： A61K39/285 , A61K9/16 , A61K39/12
CPC分类号： A61K9/1694 , A61K9/1623 , A61K9/1688 , A61K39/12 , A61K39/285 , Y02A50/388 , Y02A50/403 , Y02A50/41 , Y02A50/412 , Y02A50/414 , Y02A50/466 , Y02A50/478 , Y02A50/484
摘要： A liquid or liquid-frozen composition comprising: a modified vaccinia Ankara (MVA) virus or variant or derivative thereof and mannitol, wherein mannitol is the sole stabilization agent of the composition. The mannitol may provide a stabilizing effect at 0 to +10° C. or in a liquid-frozen composition, for example between −10° C. and −30° C. or between −20° C. and −23.5° C. The MVA may be used as a vaccine or for use in gene therapy, virotherapy, immunotherapy, or cancer therapy in a mammal, preferably a human.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式